Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MYELOMANEXT

Financiado

Cerrado

Integrated next generation flow cytometry and sequencing to uncover the pathway...

Integrated next generation flow cytometry and sequencing to uncover the pathway of curability in multiple myeloma Multiple myeloma (MM) represents a unique model to investigate cancer stem cells (CSCs), circulating tumour cells (CTCs), and the mechanisms of malignant transformation and chemoresistance. Despite the substantial improvement in M... ver más

28/02/2022

UPNA

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

UNIVERSIDAD DE NAVARRA No se ha especificado una descripción o un objeto social para esta compañía.

Total investigadores 849

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-02-28

ERC-StG-2015: ERC Starting Grant

I+D

Cerrada hace 9 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

UPNA

1.47M€ | Lider

AB AZUCARERA IBERIA

542.53K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SESAHME Spatially rEsolved Single-cell Approaches in Haematologic Ma... 174K€ Cerrado

CYTOPRO Profiling of tumour cells in blood for personalized treatmen... 71K€ Cerrado

DISSECT Disseminating tumor cells as novel biomarkers Dissecting th... 2M€ Cerrado

CanDo A CANcer Development mOnitor 5M€ Cerrado

CAREMORE Cancer Responsiveness Monitoring based on Resistance mutatio... 7M€ Cerrado

CANCER-ID Cancer treatment and monitoring through identification of ci... 21M€ Cerrado

Duración del proyecto: 66 meses Fecha Inicio: 2016-08-11
Fecha Fin: 2022-02-28

Líder del proyecto

UNIVERSIDAD DE NAVARRA No se ha especificado una descripción o un objeto social para esta compañía.

Total investigadores 849

Presupuesto del proyecto 1M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Multiple myeloma (MM) represents a unique model to investigate cancer stem cells (CSCs), circulating tumour cells (CTCs), and the mechanisms of malignant transformation and chemoresistance. Despite the substantial improvement in MM patients’ outcome, the vast majority of patients eventually relapse and the disease remains largely incurable. For those patients failing to achieve deep remissions, biologically targeted research on the ultra-chemoresistant minimal residual disease (MRD) clone may allow us to understand the cellular mechanisms driving chemoresistance, and design novel therapeutic to overcome; importantly, such effort should be equally performed on two additional key players: CSCs and CTCs. On the opposite side, it is unquestionable that a selected group of patients does experience long-term survival irrespectively of the depth of response achieved, but we fail to understand the mechanisms driving sustained disease control. Is it because of persistent residual benign clones? Is it because of immune surveillance? Here, we will integrate next-generation flow cytometry and sequencing to define i) the signature of CTCs and ultra-chemoresistant MRD cells, ii) the hierarchical place of putative CSCs, iii) the genomic landscape of benign vs. malignant clones; and iv) the role of immune surveillance to achieve functional cures. Hence, we will characterize for the first-time-ever the highly-professional subclones responsible for malignant transformation, disease dissemination, and dramatic relapses after optimal response to therapy. Noteworthy, the innovative approach of this scientific proposal strongly relies on the use and expertise of highly-sensitive next-generation flow cytometry, coupled with optimized DNA- and RNA-sequencing for low-cell-numbers, and prospective patient samples longitudinally available within the scope of well-controlled clinical trials. Herein, we believe that all requirements are met to conduct this ground-breaking research program.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores